<DOC>
	<DOCNO>NCT01654185</DOCNO>
	<brief_summary>The addition dimethyldiguanide might increase efficacy AI treatment metastatic breast cancer .</brief_summary>
	<brief_title>Dimethyldiguanide Combined With Aromatase Inhibitor ( AI ) Metastatic Breast Cancer</brief_title>
	<detailed_description>The addition dimethyldiguanide might increase efficacy AI patient metastatic breast cancer failure first line endocrine therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>postmenopausal HR positive breast cancer patient ; inoperable locally advanced metastatic breast cancer patient ; candidate endocrine therapy ; ECOG equal less 1 ; adequate bone marrow function ( Hb &gt; =90g/L , WBC &gt; =3.5×10^9/L , ANC &gt; =1.5×10^9/L , PLT &gt; =80×10^9/L ; adequate renal function ( Ccr &lt; =ULN ) ; adequate liver function ( ALT , AST , AKP &lt; =2.5*ULN , &lt; =5*ULN liver metastasis ) life expectancy &gt; =12weeks ; severe history disease liver , heart , lung kidney ; write informed consent form ; Her2 overexpression ; patient visceral endocrisis；</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>